Physician

Omar Salah Aljitawi, M.D.

According to 2025 Medicare claims, Omar Aljitawi, M.D. (NPI: 1013018415) practices hematopoietic cell transplantation and cellular therapy in the Rochester, NY market, with the plurality of this provider's patient population coming from Monroe, NY. This provider's primary affiliated billing organization is HEMATOLOGY CLINICAL GROUP (NPI: 1821049396; TIN: 166110402) and primary practice location at 14642-0001.

Aljitawi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 74 traditional Medicare patients, billed 327 HCPCS/CPT codes, and received $28,002 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 696 prescription claims across 59 beneficiaries totaling $1,746,844 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 13 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $60,986 and ending at $28,002. Concurrently, Part D prescription costs have risen steadily, from $161,479 to $1,746,844. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,196 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	218	868	$60,986
2016	171	569	$39,730
2017	30	161	$12,826
2018	39	233	$18,853
2019	42	256	$20,143
2020	58	325	$26,870
2021	70	480	$42,834
2022	61	277	$25,072
2023	77	367	$31,776
2024	74	327	$28,002

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	90	378	$161,479
2016	84	437	$317,113
2017	23	109	$24,872
2018	15	116	$5,016
2019	19	103	$10,716
2020	24	277	$83,145
2021	33	621	$547,192
2022	41	560	$784,739
2023	48	655	$1,432,923
2024	59	696	$1,746,844

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	22	$958
2024	N/R	13	$245

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	40	104	$106
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	11	11	$98
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	27	123	$88
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	22	28	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	14	26	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	91	2,744	$1,450,062
Eliquis	Apixaban	14	600	$13,041
Atovaquone	Atovaquone	11	345	$7,127
Budesonide Ec	Budesonide	12	420	$2,319
Budesonide Dr	Budesonide	27	920	$1,880

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$245

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Omar Salah Aljitawi, M.D.?

Tedicare shows public-source Medicare data for Omar Salah Aljitawi, M.D. (NPI 1013018415), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Omar Salah Aljitawi, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Omar Salah Aljitawi, M.D.?

Omar Salah Aljitawi, M.D. is linked to HEMATOLOGY CLINICAL GROUP (billing NPI 1821049396) in the available physician profile data.

Does Omar Salah Aljitawi, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.